Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

Austin G Kulasekararaj, Morag Griffin, Caroline I Piatek, Jamile Shammo, Jun-ichi Nishimura, Christopher J Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jens Peter Panse, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre de Fontbrune, Antonio Maria Risitano, Jong Wook Lee

Blood blood.2024026299.

https://doi.org/10.1182/blood.2024026299

Published: 2024

Includes: Supplemental data

Journal Articles

GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Koichi R. Katsumura, Peng Liu, Jeong-Ah Kim, Charu Mehta, Vu L. Tran, Mabel M. Jung, Kirby D. Johnson, Emery H. Bresnick

Blood (2024) 144 (Supplement 1): 4091.

https://doi.org/10.1182/blood-2024-208365

Published: 2024

Journal Articles

Assessing Cytogenetic Abnormalities in Myeloma: A Comparative Study of Hi-C, Karyotyping, and iFISH Techniques

Jing Li, Yang Yang, Chenqi Yu, Yuxia Yang, Peng Liu

Blood (2024) 144 (Supplement 1): 4700.

https://doi.org/10.1182/blood-2024-207188

Published: 2024

Journal Articles

Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics

Mabel M. Jung, Koichi R. Katsumura, Siqi Shen, Vu L. Tran, Peng Liu, Kirby D. Johnson, Sunduz Keles, Emery H. Bresnick

Blood (2024) 144 (Supplement 1): 1325.

https://doi.org/10.1182/blood-2024-210730

Published: 2024

Journal Articles

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Peng Liu, Junling Zhuang, Zhongjun Xia, Bingzong Li, Songfu Jiang, Yian Zhang, Wei Wang, Xiaoqin Chen, Xiaohui Zhang, Shujuan Zhou

Blood (2024) 144 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2024-209665

Published: 2024

Journal Articles

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Caroline Piatek, Jong Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Mohammed Mahdi, Peng Liu, Karl-Johan Myren, Andrew Messali, Flore Sicre de Fontbrune, Jens Panse, Austin G. Kulasekararaj

Blood (2024) 144 (Supplement 1): 2692.

https://doi.org/10.1182/blood-2024-199506

Published: 2024

Journal Articles

Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Wenjing Wang, Jing Li, Mengyuan Li, Xiao He, LI Bao, Xiaoqiong Tang, Hua Xue, Jianmei Xu, Liye Zhong, Peng Liu

Blood (2024) 144 (Supplement 1): 5159.

https://doi.org/10.1182/blood-2024-207888

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

YY1-Mediated PcG Regulation Dictates Hematopoietic Stem Cell Fate

Sahitya Saka, Yinghua Wang, Peng Liu, Audrey Kopp, Michael Atchison, Marjorie Brand, Xuan Pan

Blood (2024) 144 (Supplement 1): 2657.

https://doi.org/10.1182/blood-2024-203772

Published: 2024

Journal Articles

PRUNE1-IGF2BP3 Forms a Positive Feedback Loop By Stabilizing SOX4 mRNA in an m6A-Denpendent Manner to Promote Multiple Myeloma with 1q21 Gain

Yawen Wang, Peng Liu, Jiadai Xu, Panpan Li

Blood (2024) 144 (Supplement 1): 6844.

https://doi.org/10.1182/blood-2024-201516

Published: 2024

Journal Articles

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Hui-Peng Lee, Stephen S. Opat, John Hrom, David Kliman, Paula Marlton, Peng Liu, Chenmu Du, Amber Lussier, Jun Zhang, Haiyi Guo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 1661.1.

https://doi.org/10.1182/blood-2024-198728

Published: 2024

Journal Articles

Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Jiadai Xu, Peng Liu

Blood (2024) 144 (Supplement 1): 7052.

https://doi.org/10.1182/blood-2024-198093

Published: 2024

Journal Articles

Double-Hit/Triple-Hit Myeloma: An Adverse Prognostic Factor That Can be Overcome By Minimal Residual Disease Negativity

Yang Yang, Wenjing Wang, Liang Ren, Yawen Wang, Aziguli Maihemaiti, Tianwei Lan, Chi Zhou, Panpan Li, Pu Wang, Jing Li, Jiadai Xu, Tianhong Xu, Fei-fei Chen, Peng Liu

Blood (2024) 144 (Supplement 1): 6956.

https://doi.org/10.1182/blood-2024-207788

Published: 2024

Journal Articles

Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

Yuhong Ren, Jingli Zhuang, Ling Yuan, Lili Ji, Yang Ke, Peng Liu

Blood (2023) 142 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2023-186170

Published: 2023

Journal Articles

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

Austin Kulasekararaj, Morag Griffin, Caroline I Piatek, Jamile Shammo, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Anna Gaya, Yogesh Patel, Peng Liu, Gleb Filippov, Flore Sicre De Fontbrune, Antonio M Risitano, Jong-Wook Lee

Blood (2023) 142 (Supplement 1): 576.

https://doi.org/10.1182/blood-2023-189863

Published: 2023

Journal Articles

IGF2BP1 Promotes Multiple Myeloma with Chromosome 1q Gain Via Increasing CDC5L Expression in an m6A-Dependent Manner

Jiadai Xu, Peng Liu

Blood (2023) 142 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2023-185888

Published: 2023

Journal Articles

A Comparative Study of Clinical Characteristics, Cytogenetic Abnormalities and Outcomes Among Multiple Myeloma, Primary Light-Chain Amyloidosis and Multiple Myeloma with Concurrent AL Amyloidosis

Chenqi Yu, Jing Li, Tianhong Xu, Wenjing Wang, Pu Wang, Yang Yang, Peng Liu

Blood (2023) 142 (Supplement 1): 2032.

https://doi.org/10.1182/blood-2023-188350

Published: 2023

Journal Articles

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Caroline I Piatek, Jong-Wook Lee, Morag Griffin, Jun-Ichi Nishimura, Christopher J. Patriquin, Hubert Schrezenmeier, Wilma Barcellini, Jamile Shammo, Anna Gaya, Yogesh Patel, Peng Liu, Karl-Johan Myrén, Flore Sicre De Fontbrune, Jens Panse, Austin Kulasekararaj

Blood (2023) 142 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2023-190015

Published: 2023

Journal Articles

Genomic Determinants of Hematopoietic Progenitor Sensitivity to Innate Immune Signaling

Vu L. Tran, Peng Liu, Alexandra A. Soukup, Audrey Kopp, Bjorn M. Schoff, Ashley E. Mattina, Mabel M. Jung, Marjorie Brand, Kirby D. Johnson, Emery H. Bresnick

Blood (2023) 142 (Supplement 1): 5577.

https://doi.org/10.1182/blood-2023-186320

Published: 2023

NARROW

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

GATA2 Genetic Variant-Induced Pathogenesis: Loss-of-Function and Gain-of-Function Mechanisms

Assessing Cytogenetic Abnormalities in Myeloma: A Comparative Study of Hi-C, Karyotyping, and iFISH Techniques

Building a Clinical Genetic GATA2 Variant Curation System with Activity Metrics

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

YY1-Mediated PcG Regulation Dictates Hematopoietic Stem Cell Fate

PRUNE1-IGF2BP3 Forms a Positive Feedback Loop By Stabilizing SOX4 mRNA in an m6A-Denpendent Manner to Promote Multiple Myeloma with 1q21 Gain

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Double-Hit/Triple-Hit Myeloma: An Adverse Prognostic Factor That Can be Overcome By Minimal Residual Disease Negativity

Polatuzumab Vedotin, Zanubrutinib and Rituximab Achieved Rapid and Deep Response in Previously Untreated Frail and Elderly Diffuse Large B-Cell Lymphoma Patients

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data

IGF2BP1 Promotes Multiple Myeloma with Chromosome 1q Gain Via Increasing CDC5L Expression in an m6A-Dependent Manner

A Comparative Study of Clinical Characteristics, Cytogenetic Abnormalities and Outcomes Among Multiple Myeloma, Primary Light-Chain Amyloidosis and Multiple Myeloma with Concurrent AL Amyloidosis

Patient-Reported Outcomes: Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis

Genomic Determinants of Hematopoietic Progenitor Sensitivity to Innate Immune Signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only